Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany; Stress Research Institute, Stockholm University, 10691 Stockholm, Sweden; Department of Clinical Neuroscience, Division for Psychology, Karolinska Institutet, Nobels väg 9, 17177 Stockholm, Sweden.
Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.
Brain Behav Immun. 2020 Aug;88:283-293. doi: 10.1016/j.bbi.2020.05.071. Epub 2020 May 30.
Obesity is associated with an increase prevalence of neuropsychiatric symptoms and diseases, such as depression. Based on the facts that pro-inflammatory cytokines are able to modulate behavior, and that obesity is characterized by a chronic low-grade inflammatory state, inflammation has been hypothesized to contribute to the neuropsychiatric comorbidity in obese individuals. However, a causal link between inflammation and the development of neuropsychiatric symptoms is hard to establish in humans. Here, we used an inflammatory stimulus, i.e. the intravenous injection of lipopolysaccharide (LPS), in a double-blind placebo-controlled design, to determine the vulnerability of obese individuals to inflammation-induced behavioral changes. The hypothesis was that obese individuals would show heightened behavioral response compared to normal-weight subjects for the same inflammatory stimulus, reflecting an increased sensitivity to the behavioral effects of pro-inflammatory cytokines. LPS (dose 0.8 ng/kg body weight, adjusted for estimated blood volume in obese subjects) and placebo (saline) were intravenously injected in 14 obese healthy subjects and 23 normal-weight healthy subjects in a within-subject, randomized, crossover design. LPS administration induced, in both groups, an acute increase in blood concentrations of cytokines (interleukin-6, tumor necrosis factor-α, and IL-10), as well as in body temperature, cortisol, norepinephrine, sickness symptoms, fatigue, negative mood, and state anxiety. There were little differences in the immune and behavioral responses to LPS between obese and normal-weight subjects, but the cortisol response to LPS was strongly attenuated in obese individuals. Higher percentage of body fat was related to a lower cortisol response to LPS. Taken together, the population of young and healthy obese individuals in this study did not exhibit an increased behavioral sensitivity to cytokines, but an attenuated cortisol response to the immune challenge. Future studies will need to determine whether additional physiological and psychological factors interact with the state of obesity to increase the risk for inflammation-induced neuropsychiatric symptoms.
肥胖与神经精神症状和疾病的发病率增加有关,例如抑郁症。基于促炎细胞因子能够调节行为的事实,以及肥胖的特征是慢性低度炎症状态,炎症被假设为肥胖个体神经精神共病的原因。然而,在人类中,炎症与神经精神症状发展之间的因果关系很难确定。在这里,我们使用炎症刺激物,即静脉注射脂多糖(LPS),在双盲安慰剂对照设计中,确定肥胖个体对炎症引起的行为变化的易感性。假设是肥胖个体与正常体重个体相比,对于相同的炎症刺激,会表现出更高的行为反应,反映出对促炎细胞因子行为效应的敏感性增加。LPS(剂量为 0.8ng/kg 体重,根据肥胖个体的估计血容量调整)和安慰剂(盐水)以在体、随机、交叉设计静脉内注射到 14 名肥胖健康受试者和 23 名正常体重健康受试者中。LPS 给药在两组中均引起细胞因子(白细胞介素-6、肿瘤坏死因子-α和白细胞介素-10)以及体温、皮质醇、去甲肾上腺素、疾病症状、疲劳、负性情绪和状态焦虑的急性血液浓度增加。肥胖和正常体重受试者对 LPS 的免疫和行为反应差异不大,但肥胖个体对 LPS 的皮质醇反应明显减弱。体脂肪百分比越高,对 LPS 的皮质醇反应越低。总之,这项研究中的年轻和健康肥胖个体人群并没有表现出对细胞因子的行为敏感性增加,而是对免疫挑战的皮质醇反应减弱。未来的研究需要确定是否有其他生理和心理因素与肥胖状态相互作用,增加炎症引起的神经精神症状的风险。